lovastatin has been researched along with Bone Loss, Osteoclastic in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feyen, JH; French, MH; Frith, JC; Güngör, T; Harrity, TW; Rogers, MJ; Staal, A; Swartz, J; Tamasi, J | 1 |
| Coxon, FP; Hughes, DE; Luckman, SP; Rogers, MJ; Russell, GG | 1 |
| Chihara, K; Kaji, H; Kanatani, M; Sugimoto, T | 1 |
| Jadhav, SB; Jain, GK; Narayana Murthy, PS; Singh, MM | 1 |
| Cha, BY; Nagai, K; Teruya, T; Woo, JT; Yonezawa, T | 1 |
| Coxon, FP; Graham, R; Hughes, DE; Luckman, SP; Rogers, MJ; Russell, G | 1 |
| Fisher, JE; Halasy, JM; Hughes, DE; Luckman, SP; Masarachia, PJ; Reszka, AA; Rodan, GA; Rogers, MJ; Russell, RG; Wesolowski, G | 1 |
| Löwik, C; Papapoulos, S; van beek, E; van der Pluijm, G | 1 |
| Kasai, S; Nagai, K; Stern, PH; Woo, JT | 1 |
1 review(s) available for lovastatin and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation, function, and survival.
Topics: Animals; Apoptosis; Bacteria; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Survival; Cyclosporine; Depsipeptides; Fungi; Heterocyclic Compounds, 3-Ring; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Osteoclasts; Prodigiosin; Pyrans; Spiro Compounds; Tacrolimus | 2008 |
8 other study(ies) available for lovastatin and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Topics: Animals; Bone Resorption; Calcium; Female; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Osteoclasts; Osteogenesis; Parathyroidectomy; Pravastatin; Protein Prenylation; Pyridines; Rabbits; Rats; Rats, Sprague-Dawley; Simvastatin; Thyroidectomy | 2003 |
JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998).
Topics: Animals; Bone Resorption; Cells, Cultured; Diphosphonates; GTP-Binding Proteins; History, 20th Century; Lovastatin; Mevalonic Acid; Mice; Osteoclasts; Protein Prenylation; ras Proteins | 2005 |
Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Topics: Animals; Bone Resorption; Calcitriol; Carrier Proteins; Cell Differentiation; Cells, Cultured; Glycoproteins; Lovastatin; Membrane Glycoproteins; Mice; Mice, Inbred ICR; Osteoclasts; Osteogenesis; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; Simvastatin | 2005 |
Distribution of lovastatin to bone and its effect on bone turnover in rats.
Topics: Administration, Oral; Alkaline Phosphatase; Amino Acids; Animals; Area Under Curve; Bone Resorption; Carbon Radioisotopes; Chick Embryo; Cholesterol; Chromatography, High Pressure Liquid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Liver; Lovastatin; Ovariectomy; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Tibia; Time Factors; Tissue Distribution; Weight Gain | 2006 |
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Macrophages; Mevalonic Acid; Mice; Osteoclasts; Protein Prenylation; Protein Processing, Post-Translational; ras Proteins; Risedronic Acid; Structure-Activity Relationship | 1998 |
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Topics: Alendronate; Animals; Bone Resorption; Cell Differentiation; Cells, Cultured; Cholesterol; Clodronic Acid; Diterpenes; Enzyme Activation; Farnesol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Mice; Osteoclasts; Protein Kinases; Rabbits; Skull; Squalene | 1999 |
The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
Topics: Animals; Bone and Bones; Bone Resorption; Culture Techniques; Diphosphonates; Dose-Response Relationship, Drug; Female; Ibandronic Acid; Lovastatin; Mevalonic Acid; Mice; Models, Chemical; Nitrogen; Pregnancy; Protein Prenylation | 1999 |
Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.
Topics: Actins; Animals; Apoptosis; Bone Resorption; Calcitriol; Calcium; Coculture Techniques; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Lovastatin; Male; Membrane Fusion; Mevalonic Acid; Mice; Osteoclasts; Parathyroid Hormone; Polyisoprenyl Phosphates; Sesquiterpenes | 2000 |